RT Journal Article
SR Electronic
T1 Persisting Salivary IgG against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.13.21253492
DO 10.1101/2021.03.13.21253492
A1 Hassan Alkharaan
A1 Shaghayegh Bayati
A1 Cecilia Hellström
A1 Annika Olsson
A1 Karin Lindahl
A1 Gordana Bogdanovic
A1 Soo Aleman
A1 Georgios Tsilingaridis
A1 Patricia De Palma
A1 Sophia Hober
A1 Anna Månberg
A1 Peter Nilsson
A1 Elisa Pin
A1 Margaret Sällberg Chen
YR 2021
UL http://medrxiv.org/content/early/2021/03/15/2021.03.13.21253492.abstract
AB Background Declining humoral immunity in COVID-19 patients and possibility of reinfections has raised concern. Mucosal immunity particularly salivary antibodies could be short-lived. However, long-term studies are sparse.Methods Using a multiplex bead-based array platform, we investigated antibodies specific to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins in 256 saliva samples from convalescent patients 1-9 months after symptomatic COVID-19 (n=74, Cohort 1), undiagnosed individuals with self-reported questionnaires (n=147, Cohort 2), and individuals sampled pre-pandemic time (n= 35, Cohort 3).Results Salivary IgG antibody responses in Cohort 1 (mainly mild COVID-19) were detectable up to 9 month recovery, with high correlations between spike and nucleocapsid specificity. At 9 months, IgG remained in saliva in majority as seen in blood serology. Salivary IgA was rarely detected at this timepoint. In Cohort 2, salivary IgG and IgA responses were significantly associated with recent history of COVID-19 like symptoms. Salivary IgG also tolerated temperature and detergent pre-treatments.Conclusions Unlike SARS-CoV-2 salivary IgA that appeared short-lived, the specific IgG in saliva appears stable even after mild COVID-19 as noted for blood serology. The non-invasive saliva-based SARS-Cov-2 antibody testing with self-collection at homes may thus serve as a complementary alternative to conventional blood serology.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot a clinical trialFunding StatementThis study was supported by grants to Region Stockholm, Knut and Alice Wallenberg foundation, Science for Life Laboratory (SciLifeLab), Erling-Persson family foundationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the human ethical authority (dnr 2020-01702, 2020-06381)in Sweden and complied with the declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during the current study are available from the corresponding author on reasonable request.